More Topics:
Verastem Valued At Premium, InVivo Worth Even More On Innovative Therapy
Posted February 10, 2012
We Recommend...
Christoph Westphal
By Timeless Wealth
Two weeks after an IPO that saw Verastem (VSTM) successfully raise roughly $55 million, investors are valuing the pre-clinical, cancer-stem-cell targeting firm at a lofty $220 million. If it's any indication of sentiment, Verastem's valuation shows investors are willing to pay a premium for a novel technology that can differentiate itself in a crowded, yet unresolved global market. The firm's anomaly is reminiscent of InVivo Therapeutics (NVIV.OB), a company that develops technologies for the treatment of spinal cord injury (SCI). However, unlike oncology, there are no treatment options for SCI approved by the Food and Drug Administration (FDA).
Verastem's approach centers on the premise that targeted therapies should eradicate 'cancer at the root' - believed to be cancer stem cells. This approach differentiates READ FULL ARTICLE HERE
blog comments powered by